


Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins
Draupnir Bio, a cutting-edge biotechnology company, has successfully raised €12

UroGen Aims to Raise $107M to Advance Innovative Obesity and Bladder Cancer Therapies
Introduction Overview of UroGen: UroGen Pharma Ltd., headquartered in Princeton,

Forbion-Backed VectorY Therapeutics Raises $138M for ALS and Neurodegenerative Disease Research
VectorY Therapeutics, a biotechnology company based in Amsterdam, Netherlands, has
